- Clinical studies show serotonergic psychedelics may be effective in treating anxiety, depression, addiction and more
- Interest in serotonergic psychedelics has dramatically increased within last decade
- Cybin Corp. is focused on furthering research, development of psilocybin-based medications through Serenity Life Sciences Inc.
For decades seen as a taboo substance, psychedelics today are being viewed in a powerful new light. This significant societal switch is based, at least in part, on credible clinical studies, which have shown that serotonergic psychedelics may be effective in treating anxiety, depression, addiction and even cancer (http://ibn.fm/mSzY5). Cybin Corp., a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products as well as the functional mushroom market, appears to be a strong player in this developing new space.
“Scientific interest in serotonergic psychedelics . . . has dramatically increased within the last decade,” reported a recent article published by the American Society for Clinical Pharmacology and Therapeutics. “Clinical studies administering psychedelics with psychotherapy have shown preliminary evidence of robust efficacy in treating anxiety and depression, as well as addiction to tobacco and alcohol. Moreover, recent research has suggested that these compounds have potential efficacy against inflammatory diseases through novel mechanisms, with potential advantages over existing antiinflammatory agents. . . .
“Antiinflammatory effects may hold promise for efficacy in treatment of inflammation-related nonpsychiatric as well as potentially for psychiatric disorders,” the article, which was titled “Psychedelics as Medicines: An Emerging New Paradigm,” stated. “Serotonergic psychedelics operate through unique mechanisms that show promising effects for a variety of intractable, debilitating, and lethal disorders, and should be rigorously researched.”
This research has fueled growth in an industry based on psychedelic medication, a space where Cybin Corp. is emerging as a leader. The company is focused on furthering research and development of psilocybin-based medications through its wholly owned division, Serenity Life Sciences Inc. Psilocybin is a naturally occurring, non-habit-forming psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
Cybin is committed to its mission of bringing “fungi-derived psychedelic and medicinal products into the world that may potentially drive the next discovery phase of life-changing medications to treat mental illness and other health conditions.” With that mission in mind, Cybin also has a wholly owned division, called Journey Inc. that offers branded, proprietary products targeting mental wellness, the immune system, detoxification and overall general health and wellness.
Cybin is a mushroom life-sciences company advancing psychedelic and nutraceutical-based products. Cybin is launching psilocybin-based products in jurisdictions where the substance is not banned. Simultaneously, Cybin is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.